No association of FcγRIIa, FcγRIIIa and FcγRIIIb polymorphisms with MS

被引:8
|
作者
Breij, ECW
van der Pol, WL
van Winsen, L
Jansen, MD
Dijkstra, CD
van de Winkel, JGJ
Uitdehaag, BMJ
机构
[1] Vrije Univ Amsterdam, Med Ctr, Dept Mol Cell Biol, NL-1081 BT Amsterdam, Netherlands
[2] Univ Utrecht, Med Ctr, Dept Immunol, NL-3584 EA Utrecht, Netherlands
[3] Univ Utrecht, Med Ctr, Dept Neurol, NL-3584 CX Utrecht, Netherlands
[4] Vrije Univ Amsterdam, Med Ctr, Dept Neurol, NL-1081 HV Amsterdam, Netherlands
[5] Genmab, Utrecht, Netherlands
关键词
multiple sclerosis; Fc gamma receptors; polymorphisms;
D O I
10.1016/S0165-5728(03)00207-8
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Anti-myelin IgGs occur in the cerebrospinal fluid (CSF) and serum of multiple sclerosis (MS) patients, and can induce inflammatory effector functions in leukocytes by crosslinking IgG receptors (FcgammaR). The efficiency of FcgammaR-mediated inflammatory processes is affected by functional polymorphisms of three Fcgamma receptors (FcgammaRIIa, FcgammaRIIIa, FcgammaRIIIb). The relevance of FcgammaR polymorphisms in MS was evaluated by studying the distribution of FcgammaRIIa, FcgammaRIIIa and FcgammaRIIIb genotypes in 432 MS patients and 515 healthy controls. No significant differences were found between MS patients and controls, or between subgroups of patients. We conclude that Fcgamma receptor polymorphisms influence neither susceptibility nor clinical disease course of MS. (C) 2003 Elsevier B.V. All rights reserved.
引用
收藏
页码:210 / 215
页数:6
相关论文
共 50 条
  • [41] FcγRIIIA/FcγRIIIA polymorphism and its clinical association in the Korean hanyang lupus cohort.
    Yun, HR
    Yoo, DY
    Oh, YB
    Jung, JH
    Na, KS
    Kim, SS
    Kim, TH
    Jun, JB
    Jung, SS
    Lee, IH
    Bae, SC
    Salmon, JE
    Kim, SY
    ARTHRITIS AND RHEUMATISM, 1999, 42 (09): : S105 - S105
  • [42] Evidence for Linkage Disequilibrium Between FcγRIIIa-V158F and FcγRIIa-H131R Polymorphisms in White Patients, and for an FcγRIIIa-Restricted Influence on the Response to Therapeutic Antibodies
    Lejeune, Julien
    Thibault, Gilles
    Ternant, David
    Cartron, Guillaume
    Watier, Herve
    Ohresser, Marc
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (33) : 5489 - 5491
  • [43] FcγRIIB, FcγRIIIB, and systemic lupus erythematosus
    Niederer, Heather A.
    Clatworthy, Menna R.
    Willcocks, Lisa C.
    Smith, Kenneth G. C.
    YEAR IN IMMUNOLOGY 2, 2010, 1183 : 69 - 88
  • [44] FCγRIIa and FCγRIIa polymorphisms (SNPs) and cetuximab (C) benefit in the EXPERT-C trial.
    Sclafani, Francesco
    Gonzalez de Castro, David
    Cunningham, David
    Wilson, Sanna Hulkki
    Peckitt, Clare
    Capdevila, Jaume
    Glimelius, Bengt
    Keranen, Susana Rosello
    Begum, Ruwaida
    Brown, Gina
    Tait, Diana M.
    Wotherspoon, Andrew
    Thomas, Janet
    Oates, Jacqueline Rose
    Chau, Lan
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [45] Fc Gamma Receptor IIIB (FcγRIIIB) Polymorphisms Are Associated with Clinical Malaria in Ghanaian Children
    Adu, Bright
    Dodoo, Daniel
    Adukpo, Selorme
    Hedley, Paula L.
    Arthur, Fareed K. N.
    Gerds, Thomas A.
    Larsen, Severin O.
    Christiansen, Michael
    Theisen, Michael
    PLOS ONE, 2012, 7 (09):
  • [46] Structural characterization of GASDALIE Fc bound to the activating Fc receptor FcγRIIIa
    Ahmed, Alysia A.
    Keremane, Sravya R.
    Vielmetter, Jost
    Bjorkman, Pamela J.
    JOURNAL OF STRUCTURAL BIOLOGY, 2016, 194 (01) : 78 - 89
  • [47] Evidence for Linkage Disequilibrium Between FcγRIIIa-V158F and FcγRIIa-H131R Polymorphisms in White Patients, and for an FcγRIIIa-Restricted Influence on the Response to Therapeutic Antibodies IN REPLY
    Musolino, Antonino
    Naldi, Nadia
    Bortesi, Beatrice
    Pezzuolo, Debora
    Capelletti, Marzia
    Missale, Gabriele
    Laccabue, Diletta
    Zerbini, Alessandro
    Camisa, Roberta
    Bisagni, Giancarlo
    Neri, Tauro Maria
    Ardizzoni, Andrea
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (33) : 5491 - 5492
  • [48] Impact of FcγRIIa-FcγRIIIa Polymorphisms and KRAS Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan
    Bibeau, Frederic
    Lopez-Crapez, Evelyne
    Di Fiore, Frederic
    Thezenas, Simon
    Ychou, Marc
    Blanchard, France
    Lamy, Aude
    Penault-Llorca, Frederique
    Frebourg, Thierry
    Michel, Pierre
    Sabourin, Jean-Christophe
    Boissiere-Michot, Florence
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (07) : 1122 - 1129
  • [49] Distributions of FcγRIIa-131 and FcγRIIIa-158 polymorphisms and clinical response to cetuximab in Japanese patients with metastatic colorectal cancer (mCRC)
    Fukushima, H.
    Yoshino, T.
    Yamazaki, K.
    Nishina, T.
    Yuki, S.
    Kadowaki, S.
    Shinozaki, E.
    Yokota, T.
    Kajiura, S.
    Yamanaka, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [50] FcγRIIA and FcγRIIIB Are Required for Autoantibody-Induced Tissue Damage in Experimental Human Models of Bullous Pemphigoid
    Yu, Xinhua
    Holdorf, Karoline
    Kasper, Brigitte
    Zillikens, Detlef
    Ludwig, Ralf J.
    Petersen, Frank
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2010, 130 (12) : 2841 - 2844